Neurogenic Detrusor Overactivity Global Market Report 2025

Description

Neurogenic detrusor overactivity (NDO) is a bladder dysfunction that results from neurological conditions interfering with normal nerve signals between the brain, spinal cord, and the bladder's detrusor muscle. This disruption causes increased or involuntary contractions of the detrusor muscle, leading to symptoms such as urinary urgency, frequent urination, urge incontinence, and occasionally incomplete bladder emptying.

The primary treatment options for neurogenic detrusor overactivity (NDO) include non-surgical treatments, surgical interventions, and follow-up care. Non-surgical treatments involve medical management or therapies that address the condition without requiring invasive surgical procedures. These treatments are utilized across different patient groups, including both adults and children, and are delivered in various settings such as hospitals, urology clinics, rehabilitation centers, private practices, and long-term care facilities.

The neurogenic detrusor overactivity market research report is one of a series of new reports from The Business Research Company that provides neurogenic detrusor overactivity market statistics, including the neurogenic detrusor overactivity industry global market size, regional shares, competitors with the neurogenic detrusor overactivity market share, detailed neurogenic detrusor overactivity market segments, market trends, and opportunities, and any further data you may need to thrive in the neurogenic detrusor overactivity industry. These neurogenic detrusor overactivity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurogenic detrusor overactivity market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The historic growth is attributed to a rise in neurological disorders, increased awareness among healthcare providers, broader adoption of pharmaceutical treatments, development of hospital and clinic facilities, and higher diagnosis rates.

The neurogenic detrusor overactivity market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Growth drivers for the forecast period include the aging population, rising cases of spinal cord injuries, increased healthcare spending, advancements in minimally invasive therapies, and enhanced patient awareness and education. Key trends during this period include technological progress in stem cell therapies, innovation in drug delivery systems, improvements in neuromodulation devices, advances in personalized medicine research, and the development of less invasive treatment procedures.

The rising incidence of neurological disorders is expected to drive the growth of the neurogenic detrusor overactivity (NDO) market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, or nerves, resulting in issues with movement, sensation, cognition, or other bodily functions. As people live longer, the likelihood of age-related brain degeneration increases, contributing to the growing prevalence of these conditions. NDO is a form of bladder dysfunction often linked to neurological disorders such as spinal cord injury, multiple sclerosis, and Parkinson's disease. These conditions interfere with normal nerve communication between the brain and bladder, leading to involuntary bladder contractions. For example, in April 2024, a study published by the American Academy of Neurology (AAN) indicated that there will be an estimated 4.9 billion cases of brain disorders globally by 2050, marking a 22% increase from around 4 billion cases in 2021. Consequently, the increasing number of neurological disorders is contributing to the expansion of the NDO market.

Major companies involved in the treatment of neurogenic detrusor overactivity are emphasizing the development of advanced generic therapies, such as beta-3 adrenergic receptor agonists, to provide effective bladder control solutions at lower costs. These drugs, such as mirabegron, help relax the detrusor muscle in the bladder, thereby enhancing bladder capacity and reducing symptoms like urgency and incontinence. For instance, in April 2024, Lupin Ltd., an Indian pharmaceutical company, received approval from the U.S. Food and Drug Administration (USFDA) to launch Mirabegron, a generic version of Myrbetriq, in the United States. As a once-daily oral treatment, Mirabegron provides a convenient and efficient option for managing overactive bladder (OAB) and neurogenic detrusor overactivity in pediatric patients. This approval underscores Lupin's commitment to offering high-quality and affordable generic medications in key therapeutic areas.

In November 2024, Boston Scientific Corporation, a U.S.-based medical device company, acquired Axonics, Inc. to strengthen its portfolio in neuromodulation and urology. This acquisition aims to enhance Boston Scientific's capabilities in treating overactive bladder and other urinary and bowel dysfunctions by incorporating Axonics' innovative sacral neuromodulation technologies. The integration of Axonics' solutions will allow Boston Scientific to offer more comprehensive care options for pelvic health conditions. Axonics, Inc. is a U.S.-based medical technology firm that specializes in sacral neuromodulation systems designed to improve bladder control.

Major players in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., and Hugel Inc.

North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in neurogenic detrusor overactivity report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurogenic detrusor overactivity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenic detrusor overactivity market includes revenues earned by entities by providing services such as medication management, behavioral and lifestyle interventions, physiotherapy, absorbent products and skin care, and catheterization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenic Detrusor Overactivity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenic detrusor overactivity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurogenic detrusor overactivity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurogenic detrusor overactivity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Types: Non-Surgical Treatment; Surgical Treatment; Follow-Up Treatment
2) By Application: Adult; Child
3) By End-User: Hospitals; Urology Clinics; Rehabilitation Centers; Private Practices; Long-Term Care Facilities
Subsegments:
1) By Non-Surgical Treatment: Antimuscarinic Drugs; Beta-3 Adrenergic Agonists; Behavioral Therapy; Neuromodulation; Clean Intermittent Catheterization; Intravesical Therapies
2) By Surgical Treatment: Botulinum Toxin Injection; Augmentation Cystoplasty; Urinary Diversion; External Sphincterotomy; Artificial Urinary Sphincter Implantation
3) By Follow-Up Treatment: Urodynamic Evaluation; Ultrasound Monitoring; Laboratory Tests; Ongoing Catheterization; Repeat Botulinum Toxin Injections; Patient and Caregiver Training; Quality of Life Assessment
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Sanofi S. A.; Medtronic plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r35987

1. Executive Summary

2. Neurogenic Detrusor Overactivity Market Characteristics

3. Neurogenic Detrusor Overactivity Market Trends And Strategies

4. Neurogenic Detrusor Overactivity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurogenic Detrusor Overactivity Growth Analysis And Strategic Analysis Framework

5.1. Global Neurogenic Detrusor Overactivity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurogenic Detrusor Overactivity Market Growth Rate Analysis
5.4. Global Neurogenic Detrusor Overactivity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurogenic Detrusor Overactivity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurogenic Detrusor Overactivity Total Addressable Market (TAM)

6. Neurogenic Detrusor Overactivity Market Segmentation

6.1. Global Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Surgical Treatment
Surgical Treatment
Follow-Up Treatment
6.2. Global Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult
Child
6.3. Global Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Urology Clinics
Rehabilitation Centers
Private Practices
Long-Term Care Facilities
6.4. Global Neurogenic Detrusor Overactivity Market, Sub-Segmentation Of Non-Surgical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antimuscarinic Drugs
Beta-3 Adrenergic Agonists
Behavioral Therapy
Neuromodulation
Clean Intermittent Catheterization
Intravesical Therapies
6.5. Global Neurogenic Detrusor Overactivity Market, Sub-Segmentation Of Surgical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Botulinum Toxin Injection
Augmentation Cystoplasty
Urinary Diversion
External Sphincterotomy
Artificial Urinary Sphincter Implantation
6.6. Global Neurogenic Detrusor Overactivity Market, Sub-Segmentation Of Follow-Up Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Urodynamic Evaluation
Ultrasound Monitoring
Laboratory Tests
Ongoing Catheterization
Repeat Botulinum Toxin Injections
Patient and Caregiver Training
Quality of Life Assessment

7. Neurogenic Detrusor Overactivity Market Regional And Country Analysis

7.1. Global Neurogenic Detrusor Overactivity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurogenic Detrusor Overactivity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurogenic Detrusor Overactivity Market

8.1. Asia-Pacific Neurogenic Detrusor Overactivity Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurogenic Detrusor Overactivity Market

9.1. China Neurogenic Detrusor Overactivity Market Overview
9.2. China Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurogenic Detrusor Overactivity Market

10.1. India Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurogenic Detrusor Overactivity Market

11.1. Japan Neurogenic Detrusor Overactivity Market Overview
11.2. Japan Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurogenic Detrusor Overactivity Market

12.1. Australia Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurogenic Detrusor Overactivity Market

13.1. Indonesia Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurogenic Detrusor Overactivity Market

14.1. South Korea Neurogenic Detrusor Overactivity Market Overview
14.2. South Korea Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurogenic Detrusor Overactivity Market

15.1. Western Europe Neurogenic Detrusor Overactivity Market Overview
15.2. Western Europe Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurogenic Detrusor Overactivity Market

16.1. UK Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurogenic Detrusor Overactivity Market

17.1. Germany Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurogenic Detrusor Overactivity Market

18.1. France Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurogenic Detrusor Overactivity Market

19.1. Italy Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurogenic Detrusor Overactivity Market

20.1. Spain Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurogenic Detrusor Overactivity Market

21.1. Eastern Europe Neurogenic Detrusor Overactivity Market Overview
21.2. Eastern Europe Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurogenic Detrusor Overactivity Market

22.1. Russia Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurogenic Detrusor Overactivity Market

23.1. North America Neurogenic Detrusor Overactivity Market Overview
23.2. North America Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurogenic Detrusor Overactivity Market

24.1. USA Neurogenic Detrusor Overactivity Market Overview
24.2. USA Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurogenic Detrusor Overactivity Market

25.1. Canada Neurogenic Detrusor Overactivity Market Overview
25.2. Canada Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurogenic Detrusor Overactivity Market

26.1. South America Neurogenic Detrusor Overactivity Market Overview
26.2. South America Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurogenic Detrusor Overactivity Market

27.1. Brazil Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurogenic Detrusor Overactivity Market

28.1. Middle East Neurogenic Detrusor Overactivity Market Overview
28.2. Middle East Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurogenic Detrusor Overactivity Market

29.1. Africa Neurogenic Detrusor Overactivity Market Overview
29.2. Africa Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurogenic Detrusor Overactivity Market Competitive Landscape And Company Profiles

30.1. Neurogenic Detrusor Overactivity Market Competitive Landscape
30.2. Neurogenic Detrusor Overactivity Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S. A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis

31. Neurogenic Detrusor Overactivity Market Other Major And Innovative Companies

31.1. Teva Pharmaceutical Industries Ltd.
31.2. Astellas Pharma Inc.
31.3. Intas Pharmaceuticals Ltd.
31.4. Macleods Pharmaceuticals Ltd.
31.5. Sun Pharmaceutical Industries
31.6. Apotex Inc.
31.7. Viatris Inc.
31.8. Sumitomo Pharma America Inc.
31.9. Galderma
31.10. Ipsen
31.11. Coloplast A/S
31.12. Aurobindo Pharma Limited
31.13. Hisamitsu Pharmaceutical Co. Inc.
31.14. Kaken Pharmaceutical Co. Ltd.
31.15. Hugel Inc.

32. Global Neurogenic Detrusor Overactivity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurogenic Detrusor Overactivity Market

34. Recent Developments In The Neurogenic Detrusor Overactivity Market

35. Neurogenic Detrusor Overactivity Market High Potential Countries, Segments and Strategies

35.1 Neurogenic Detrusor Overactivity Market In 2029 - Countries Offering Most New Opportunities
35.2 Neurogenic Detrusor Overactivity Market In 2029 - Segments Offering Most New Opportunities
35.3 Neurogenic Detrusor Overactivity Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer